公开(公告)号：US06890930B1

公开(公告)日：2005-05-10

申请号：US10089166

申请日：2000-09-13

Applicant: Werner Mederski ,  Maria Devant ,  Gerhard Barnickel ,  Sabine Bernotat-Danielowski ,  Guido Melzer ,  Bertram Cezane ,  Dalijit Dhanoa ,  Bao-Ping Zhoa ,  James Rinker ,  Mark Player ,  Richard Soll

Inventor： Ralf Devant

IPC: A61K31/505 ,  A61K31/517 ,  C07D239/72 ,  C07D239/74 ,  C07D239/91 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04

CPC classification number: C07D405/06 ,  C07D239/91 ,  C07D405/04 ,  C07D409/04

Abstract: Quinazolinones of formula (I) in which R, R1, R2, R3, R4, Y, Z, and m have the meaning indicated in patent claim 1, and their salts or solvates as glycoprotein IbIX antagonists.

Abstract translation: 式（I）的喹唑啉酮，其中R 1，R 2，R 2，R 3，R 4， Y，Z和m具有专利权利要求1中所示的含义，其盐或溶剂合物作为糖蛋白IbIX拮抗剂。

公开(公告)号：US08796256B2

公开(公告)日：2014-08-05

申请号：US13114084

申请日：2011-05-24

Applicant: Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

Inventor： Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

IPC: C07D417/06

CPC classification number: C07D417/06

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖，升高的血糖水平和胰岛素抵抗。

公开(公告)号：US20090171089A1

公开(公告)日：2009-07-02

申请号：US12399292

申请日：2009-03-06

Applicant: Charles L. CYWIN ,  Scott E. JAKES ,  Joachim HEIDER ,  Mark A. BOBKO ,  Renee L. DES JARLAIS ,  Mark PLAYER ,  James RINKER ,  Michael WINTERS ,  Bao-ping ZHAO

Inventor： Charles L. CYWIN ,  Scott E. JAKES ,  Joachim HEIDER ,  Mark A. BOBKO ,  Renee L. DES JARLAIS ,  Mark PLAYER ,  James RINKER ,  Michael WINTERS ,  Bao-ping ZHAO

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Disclosed are compounds of formula (I): wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

Abstract translation: 公开了式（I）的化合物：其中R 3，R 5，R 7和R 8在本文中定义，其可用作抑制剂SYK激酶，因此可用于治疗由不适当的肥大细胞活化引起的疾病，包括过敏性和炎性疾病。 还公开了包含这些化合物的药物组合物和制备这些化合物的方法。

公开(公告)号：US20080114024A1

公开(公告)日：2008-05-15

申请号：US12014190

申请日：2008-01-15

Applicant: Charles CYWIN ,  Scott Jakes ,  Joachim Heider ,  Mark Bobko ,  Renee Des Jarlais ,  Mark Player ,  James Rinker ,  Michael Winters ,  Bao-ping Zhao

Inventor： Charles CYWIN ,  Scott Jakes ,  Joachim Heider ,  Mark Bobko ,  Renee Des Jarlais ,  Mark Player ,  James Rinker ,  Michael Winters ,  Bao-ping Zhao

IPC: A61K31/44 ,  C07D471/02 ,  A61P43/00

CPC classification number: C07D471/04

Abstract: Disclosed are compounds of formula (I): wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

Abstract translation: 公开了式（I）的化合物：其中R 3，R 5，R 7和R 8是 其可用作抑制剂SYK激酶，因此可用于治疗由不适当的肥大细胞活化引起的疾病，包括过敏性和炎性疾病。 还公开了包含这些化合物的药物组合物和制备这些化合物的方法。

公开(公告)号：US20070060578A1

公开(公告)日：2007-03-15

申请号：US11519662

申请日：2006-09-12

Applicant: Mark Player ,  Hui Huang ,  Hu Huaping

Inventor： Mark Player ,  Hui Huang ,  Hu Huaping

IPC: A61K31/541 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/496 ,  C07D487/02 ,  C07D471/02

CPC classification number: C07D471/04

Abstract: The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein:W, A, Y, n, Z, and R102 are described in the specification.

Abstract translation: 本发明通过提供c-fms激酶的有效抑制剂来解决当前对选择性和有效的蛋白酪氨酸激酶抑制剂的需要。 本发明涉及新的式I化合物或其溶剂化物，水合物，互变异构体或其药学上可接受的盐，其中：W，A，Y，n，Z和R 102描述于 规格。

公开(公告)号：US20060106022A1

公开(公告)日：2006-05-18

申请号：US11233725

申请日：2005-09-23

Applicant: Jian Liu ,  Raymond Patch ,  Mark Player

Inventor： Jian Liu ,  Raymond Patch ,  Mark Player

IPC: C07D487/02 ,  A61K31/498

CPC classification number: C07D487/04

Abstract: The invention is directed to compounds of Formula I: wherein Q, Y, A are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein kinases, especially Aurora-1, Aurora-2 and Aurora-3 kinases.

公开(公告)号：US06910127B1

公开(公告)日：2005-06-21

申请号：US10023019

申请日：2001-12-18

Applicant: Andrew Mark Player

Inventor： Andrew Mark Player

IPC: G06F9/445 ,  G06F15/177

CPC classification number: G06F9/4411

Abstract: A system and method have been provided for securely provisioning configuration data in a network-connected integrated circuit device. The method comprises: receiving configuration data addressed to device registers; loading the configuration data in configuration registers; and, locking to prevent the loading of subsequently received configuration data. Locking to prevent the loading of subsequently received configuration data includes the substeps of: establishing at least one locking register having a first address; loading a first lock set in the locking register; and, in response to loading the first lock set in the locking register, preventing the loading of received data in the configuration registers.

Abstract translation: 已经提供了一种用于在网络连接的集成电路设备中安全地配置配置数据的系统和方法。 该方法包括：接收寻址到设备寄存器的配置数据; 将配置数据加载到配置寄存器中; 并锁定以防止后续接收的配置数据的加载。 锁定以防止随后接收的配置数据的加载包括以下子步骤：建立至少一个具有第一地址的锁定寄存器; 加载锁定寄存器中的第一个锁定集; 并且响应于加载锁定寄存器中的第一锁定集，防止在配置寄存器中加载接收到的数据。

公开(公告)号：US20050131022A1

公开(公告)日：2005-06-16

申请号：US10970865

申请日：2004-10-22

Applicant: Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

Inventor： Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

IPC: A61K31/16 ,  A61K31/195 ,  A61K31/452 ,  A61K31/4545 ,  C07D223/12 ,  C07D265/30 ,  C07D279/12 ,  C07D307/68 ,  C07D405/12 ,  C07D409/12 ,  C07D45/02

CPC classification number: C07D405/12 ,  C07D207/416 ,  C07D233/90 ,  C07D307/68 ,  C07D409/12

Abstract: The invention is directed to compounds of Formulae I: wherein A, R1, R2, R3, R4, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Abstract translation: 本发明涉及式I的化合物：其中A，R 1，R 2，R 3，R 4， 说明书中列出了SUB，X和W，以及其抑制蛋白酪氨酸激酶，特别是c-fms激酶的溶剂合物，水合物，互变异构体或其药学上可接受的盐。

公开(公告)号：US20050049274A1

公开(公告)日：2005-03-03

申请号：US10894940

申请日：2004-07-20

Applicant: Mark Wall ,  Mark Player ,  Raymond Patch ,  Sanath Meegalla ,  Jian Liu ,  Carl Illig ,  Wing Cheung ,  Jinsheng Chen ,  Davoud Asgari

Inventor： Mark Wall ,  Mark Player ,  Raymond Patch ,  Sanath Meegalla ,  Jian Liu ,  Carl Illig ,  Wing Cheung ,  Jinsheng Chen ,  Davoud Asgari

IPC: A61P35/00 ,  C07D215/22 ,  C07D215/227 ,  C07D401/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D471/02 ,  A61K31/47 ,  C07D215/36

CPC classification number: C07D215/227 ,  C07D401/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  Y02P20/582

Abstract: The invention is directed to compounds of Formulae I and II: wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Abstract translation: 本发明涉及式I和II的化合物：其中R 1，R 2，R 3，R 5，R 6，Y 1，Y 2， 3>，Y 4和X在说明书中列出，以及其抑制蛋白酪氨酸激酶，特别是c-fms激酶的溶剂合物，水合物，互变异构体或其药学上可接受的盐。

公开(公告)号：US20050004112A1

公开(公告)日：2005-01-06

申请号：US10831216

申请日：2004-04-26

Applicant: Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

Inventor： Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

IPC: A61K31/16 ,  A61K31/195 ,  A61K31/452 ,  A61K31/4545 ,  A61K31/55 ,  A61P35/00 ,  C07D207/34 ,  C07D207/42 ,  C07D213/81 ,  C07D223/12 ,  C07D231/16 ,  C07D231/38 ,  C07D261/18 ,  C07D265/02 ,  C07D265/30 ,  C07D279/12 ,  C07D295/14 ,  C07D307/68 ,  C07D307/71 ,  C07D307/72 ,  C07D401/12 ,  C07D405/00 ,  C07D405/12 ,  C07D491/04

CPC classification number: C07D213/81 ,  C07D231/38 ,  C07D265/02 ,  C07D307/68 ,  C07D307/71 ,  C07D405/12 ,  C07D491/04

Abstract: The invention is directed to compounds of Formulae I, II and III: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Abstract translation: 本发明涉及式I，II和III的化合物：其中A，R 1，R 2，R 3，R 4，X，Y和W在说明书中列出，以及溶剂合物，水合物，互变异构体或其药学上可接受的盐 ，抑制蛋白酪氨酸激酶，特别是c-fms激酶。